| Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment M Zhang, JL Luo, Q Sun, J Harber, AG Dawson, A Nakas, S Busacca, ... Nature communications 12 (1), 1751, 2021 | 81 | 2021 |
| Medical and surgical care of patients with mesothelioma and their relatives carrying germline BAP1 mutations M Carbone, HI Pass, G Ak, HR Alexander Jr, P Baas, F Baumann, ... Journal of Thoracic Oncology 17 (7), 873-889, 2022 | 58 | 2022 |
| CD40L/IL-4–stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM L Lezina, RV Spriggs, D Beck, C Jones, KM Dudek, A Bzura, GDD Jones, ... Blood advances 2 (15), 1869-1881, 2018 | 20 | 2018 |
| P2. 06-02 mesothelioma stratified therapy (MiST): a phase IIA umbrella trial for accelerating the development of precision medicines D Fennell, M Hudka, L Darlison, K Lord, A Bzura, J Dzialo, C Pritchard, ... Journal of Thoracic Oncology 14 (10), S755-S756, 2019 | 10 | 2019 |
| ATM Regulates differentiation of myofibroblastic cancer-associated fibroblasts and can be targeted to overcome immunotherapy resistance M Mellone, K Piotrowska, G Venturi, L James, A Bzura, MA Lopez, ... Cancer Research 82 (24), 4571-4585, 2022 | 9 | 2022 |
| Precision therapy for mesothelioma: Feasibility and new opportunities S Dulloo, A Bzura, DA Fennell Cancers 13 (10), 2347, 2021 | 5 | 2021 |
| BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms A Singh, S Busacca, A Gaba, M Sheaff, C Poile, A Nakas, J Dzialo, ... Oncogene 42 (8), 572-585, 2023 | 4 | 2023 |
| Family Matters: Germline Testing in Thoracic Cancers F Hathaway, R Martins, S Sorscher, A Bzura, F Dudbridge, DA Fennell American Society of Clinical Oncology Educational Book 43, e389956, 2023 | 2 | 2023 |
| Accelerating innovations in systemic therapy for pleural mesothelioma DA Fennell, A Bzura Nature Cancer 3 (8), 902-904, 2022 | 2 | 2022 |
| 61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma B Cunniff, T Messier, V Gibson, D Seward, E Baitei, PW Jordan, C Poile, ... Lung Cancer 190, 107622, 2024 | | 2024 |
| SLC7A11 modulates sensitivity to the first-in-class mitochondrial peroxiredoxin 3 inhibitor thiostrepton (RSO-021) via a ferroptosis independent pathway T Messier, V Gibson, A Bzura, J Dzialo, C Poile, S Stead, A Saaman, ... Cancer Research 84 (6_Supplement), 384-384, 2024 | | 2024 |
| First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in mesothelioma T Messier, V Gibson, DJ Seward, EY Baitei, PW Jordan, C Poile, J Dzialo, ... Cancer Research 84 (6_Supplement), 4716-4716, 2024 | | 2024 |
| ASTX295 engages p53-mediated apoptosis and an inflammatory response in patient derived mesothelioma explants DA Fennell, J Dzialo, J Rogel, D Faulkner, N Nusrat, A Bzura, K Kutywayo, ... Cancer Research 84 (6_Supplement), 666-666, 2024 | | 2024 |
| Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label … D Fennell, D Griffiths, Z Eminton, A Morgan-Fox, K Hill, S Ewings, C Stuart, ... BMJ open 13 (11), e073120, 2023 | | 2023 |
| MA17. 11 Spatial Transformation in Mesothelioma Involves a Hypoxia-TGF Beta-EMT axis that is Reversible via PRX3 Inhibition M Zhang, T Messier, A Nakas, P Wells-Jordan, C Poile, D Seward, ... Journal of Thoracic Oncology 18 (11), S165, 2023 | | 2023 |
| P2. 18-02 Successful Generation of Tumor-Infiltrating Lymphocytes (TIL) for Adoptive Cell Therapy from Mesothelioma DA Fennell, C Poile, A Bzura, J Dzialo, A Nakas, K Kutywayo, A Natarajan, ... Journal of Thoracic Oncology 18 (11), S381-S382, 2023 | | 2023 |
| A gut microbiota rheostat to forecast response to PDL1-VEGF blockade in mesothelioma. DA Fennell, A Bzura, A Branson, A King, J Rogel, S Barber, C Poile, ... Journal of Clinical Oncology 41 (16_suppl), e20534-e20534, 2023 | | 2023 |
| Targeting DNA damage deficient mesotheliomas via synthetic lethal disruption of DNA double-strand repair A Bzura University of Leicester, 2023 | | 2023 |
| Protocol: Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm … D Fennell, D Griffiths, Z Eminton, A Morgan-Fox, K Hill, S Ewings, C Stuart, ... BMJ Open 13 (11), 2023 | | 2023 |
| Niraparib efficacy in patients with unresectable mesothelioma: a randomised phase II trial of niraparib versus active symptom control in patients with previously treated … D Fennell, D Griffiths, Z Eminton, A Morgan-Fox, K Hill, T Nearchou, ... | | 2023 |
